Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.

@article{Nabhan2002SecondaryAM,
  title={Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.},
  author={Chadi Nabhan and Lisa A Peterson and Sara A Kent and Martin S. Tallman and Gordon Dewald and Pratik S. Multani and Leo I Gordon},
  journal={Leukemia & lymphoma},
  year={2002},
  volume={43 11},
  pages={2145-9}
}
Targeted therapy with conjugated and unconjugated monoclonal antibodies for non-Hodgkin's lymphoma has revolutionized the approach to this disease. The efficacy and low toxicity of these agents have allowed introduction of this strategy in the early stages of therapy. Longer follow-up is needed before validating the safety of these agents. Since monoclonal antibodies are being given as front-line therapy, it is important to identify all potential adverse events. We report a case of secondary… CONTINUE READING